Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts

Toxicology

Volumn 334, Issue , 2015, Pages 1-11

  Deus, Cláudia M ^a   Zehowski, Cheryl ^b   Nordgren, Kendra ^b   Wallace, Kendall B ^b   Skildum, Andrew ^b   Oliveira, Paulo J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Doxorubicin; H9c2 myoblasts; Mitochondrial capacity; Toxicity; Troglitazone

Indexed keywords

CASPASE 3; CASPASE 9; DOXORUBICIN; GALACTOSE; MITOCHONDRIAL DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; CHROMAN DERIVATIVE; CULTURE MEDIUM;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER CELL LINE; CARDIOTOXICITY; CULTURE MEDIUM; CYTOTOXICITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL RESPIRATION; COMPARATIVE STUDY; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HEART MITOCHONDRION; MCF 7 CELL LINE; METABOLISM; MITOCHONDRIAL DYNAMICS; MYOBLAST; PATHOLOGY; TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL RESPIRATION; CHROMANS; CULTURE MEDIA; DNA REPLICATION; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MCF-7 CELLS; MITOCHONDRIA, HEART; MITOCHONDRIAL TURNOVER; MYOBLASTS, CARDIAC; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RATS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TIME FACTORS; UP-REGULATION;

EID: 84929575716     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.05.001     Document Type: Article

References (46)

1. Ascensao A., Magalhaes J., Soares J.M.C., Ferreira R., Neuparth M.J., Marques F., Oliveira P.J., Duarte J.A. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H722-H731.
2. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
3. Bova M.P., Tam D., McMahon G., Mattson M.N. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol. Lett. 2005, 155:41-50.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Broder H., Gottlieb R.A., Lepor N.E. Chemotherapy and cardiotoxicity. Rev. Cardiovasc. Med. 2008, 9:75-83.
6. Carvalho F.S., Burgeiro A., Garcia R., Moreno A.J., Carvalho R.A., Oliveira P.J. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med. Res. Rev. 2014, 34(1):106-135.
7. Danz E.D.B., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radical Biol. Med. 2009, 46:1589-1597.
8. Davies G.F., Roesler W.J., Juurlink B.H., Harkness T.A. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk. Lymphoma 2005, 46:1199-1206.
9. Davies G.F., Juurlink B.H., Harkness T.A. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des. Dev. Ther. 2009, 3:79-88.
10. Davies G.F., Ross A.R., Arnason T.G., Juurlink B.H., Harkness T.A. Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett. 2010, 288:236-250.
11. Divakaruni A.S., Wiley S.E., Rogers G.W., Andreyev A.Y., Petrosyan S., Loviscach M., Wall E.A., Yadava N., Heuck A.P., Ferrick D.A., Henry R.R., McDonald W.G., Colca J.R., Simon M.I., Ciaraldi T.P., Murphy A.N. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5422-5427.
12. Dodd D.A., Atkinson J.B., Olson R.D., Buck S., Cusack B.J., Fleischer S., Boucek R.J. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 1993, 91:1697-1705.
13. Dykens J.A., Jamieson J., Marroquin L., Nadanaciva S., Billis P.A., Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol. Appl. Pharmacol. 2008, 233:203-210.
14. Graef M., Nunnari J. Mitochondria regulate autophagy by conserved signalling pathways. EMBO J. 2011, 30:2101-2114.
15. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
16. Kawaguchi T., Takemura G., Kanamori H., Takeyama T., Watanabe T., Morishita K., Ogino A., Tsujimoto A., Goto K., Maruyama R., Kawasaki M., Mikami A., Fujiwara T., Fujiwara H., Minatoguchi S. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc. Res. 2012, 96:456-465.
17. Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J. Biol. Chem. 2010, 285:793-804.
18. Konorev E.A., Vanamala S., Kalyanaraman B. Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radical Biol. Med. 2008, 45:1723-1728.
19. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
20. Lin Z.X., Hoult J.R.S., Raman A. Sulphorhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J. Ethnopharmacol. 1999, 66:141-150.
21. Lu L., Wu W., Yan J., Li X., Yu H., Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol. 2009, 134:82-90.
22. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547.
23. Momparler R.L., Karon M., Siegel S.E., Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976, 36:2891-2895.
24. Moreira A.C., Branco A.F., Sampaio S.F., Cunha-Oliveira T., Martins T.R., Holy J., Oliveira P.J., Sardao V.A. Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts. Biochim. Biophys. Acta 2014, 1842:2468-2478.
25. Nadanaciva S., Dykens J.A., Bernal A., Capaldi R.A., Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 2007, 223:277-287.
26. Okuda T., Norioka M., Shitara Y., Horie T. Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition. Toxicol. Appl. Pharmacol. 2010, 248:242-248.
27. Rachek L.I., Yuzefovych L.V., Ledoux S.P., Julie N.L., Wilson G.L. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 2009, 240:348-354.
28. Rana P., Nadanaciva S., Will Y. Mitochondrial membrane potential measurement of H9c2 cells grown in high-glucose and galactose-containing media does not provide additional predictivity towards mitochondrial assessment. Toxicol. In Vitro 2011, 25:580-587.
29. Rehman J., Zhang H.J., Toth P.T., Zhang Y., Marsboom G., Hong Z., Salgia R., Husain A.N., Wietholt C., Archer S.L. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012, 26:2175-2186.
30. Romero-Calvo I., Ocon B., Martinez-Moya P., Suarez M.D., Zarzuelo A., Martinez-Augustin O., de Medina F.S. Reversible Ponceau staining as a loading control alternative to actin in western blots. Anal. Biochem. 2010, 401:318-320.
31. Rossignol R., Gilkerson R., Aggeler R., Yamagata K., Remington S.J., Capaldi R.A. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004, 64:985-993.
32. Sardao V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell. Biol. Toxicol. 2009, 25:227-243.
33. Sigmund, W., 1999. Important prescribing information for troglitazone (Rezulin) [Dear Healthcare Professional letter]. Morris Plains, NJ: Parke-Davis/Warner Lambert; June 17, 1999. Available from: http://google2.fda.gov/search%3Fq=rezulin&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=
34. Sishi B.J., Loos B., van Rooyen J., Engelbrecht A.M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem. Pharmacol. 2013, 85:124-134.
35. Skildum A., Dornfeld K., Wallace K. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. Breast Cancer Res. Treat. 2011, 129:785-797.
36. Smuder A.J., Kavazis A.N., Min K., Powers S.K. Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. J. Appl. Physiol. 2013, 115:176-185.
37. Solem L.E., Henry T.R., Wallace K.B. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 1994, 129:214-222.
38. Subbarayan V., Sabichi A.L., Kim J., Llansa N., Logothetis C.J., Lippman S.M., Menter D.G. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1710-1716.
39. Sun J.X., Meng Z.X., Lv J.H., Sun Y.J. Troglitazone sensitizes effect of epirubicin on breast cancer cells. Ai Zheng 2006, 25:960-966.
40. Terashita Y., Sasaki H., Haruki N., Nishiwaki T., Ishiguro H., Shibata Y., Kudo J., Konishi S., Kato J., Koyama H., Kimura M., Sato A., Shinoda N., Kuwabara Y., Fujii Y. Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn. J. Clin. Oncol. 2002, 32:238-243.
41. Tirmenstein M.A., Hu C.X., Gales T.L., Maleeff B.E., Narayanan P.K., Kurali E., Hart T.K., Thomas H.C., Schwartz L.W. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 2002, 69:131-138.
42. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 2003, 93:105-115.
43. Yan J., Yang H., Wang G., Sun L., Zhou Y., Guo Y., Xi Z., Jiang X. Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling. Autophagy 2010, 6:67-73.
44. Zhang C., Feng Y., Qu S., Wei X., Zhu H., Luo Q., Liu M., Chen G., Xiao X. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res. 2011, 90:538-545.
45. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18:1639-1642.
46. Zhou S., Palmeira C.M., Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 2001, 121:151-157.